The global enalapril market​ is projected to reach USD 3.9 billion by 2024, demonstrating a steady compound annual growth rate (CAGR) of 4.15%​ through 2032 . This essential angiotensin-converting enzyme (ACE) inhibitor has maintained critical importance in cardiovascular therapeutic applications worldwide, particularly for hypertension and heart failure management. Understanding the dynamic global buyer landscape​ for enalapril has become increasingly valuable for pharmaceutical suppliers, distributors, and stakeholders seeking to capitalize on established market opportunities. This comprehensive analysis examines key purchasing regions, procurement patterns, supplier capabilities, and strategic considerations defining the global enalapril trade ecosystem. 1. Market Overview and Therapeutic Applications Driving Demand The persistent global prevalence of cardiovascular diseases​ has sustained…